Chugai Pharma Focuses On Licensing Antibody Mass-Production Methods
This article was originally published in PharmAsia News
Chugai Pharmaceutical has embarked on a global effort to license its antibody drug mass-production technology, with a focus on Europe and the U.S.
You may also be interested in...
In the only device-related warning letter released by the US FDA this week, Avazo Healthcare was selling two COVID-19 antigen tests without approval, clearance or authorization from the agency.
A sharp decline in the number of in-person facility inspections has forced the FDA to consider creative techniques for remotely evaluating manufacturer compliance during the COVID-19 pandemic. This and other stories topped our list of most-read Medtech Insight articles in November.
A package of health proposals intended to build up the EU’s resilience to health threats while strengthening the competitiveness of Europe’s pharmaceutical industry and ensuring access to affordable drugs takes a major step through the legislative process this week.